Calcitonin and the thyroid C-cell warning: what the labels say about testing, in their own words

Calcitonin is the test people ask about after reading the boxed warning, and the one the labels most clearly say not to run routinely. That is not a contradiction. The warning tells you what is uncertain; the testing sentence tells you what a blood test can and cannot do about it. This page keeps to what the labels and MedlinePlus say.

What calcitonin is

Calcitonin is a hormone made by the parafollicular cells, or C cells, of the thyroid. It plays a minor role in calcium regulation. Its clinical importance is as a tumor marker: medullary thyroid carcinoma (MTC) arises from C cells and usually secretes calcitonin, so a very high level suggests MTC and a rising level after treatment suggests recurrence. MedlinePlus gives a common normal value of under 25 pg/mL for men and under 20 pg/mL for women, notes that men have higher values, and describes a stimulation test used when the baseline is normal but suspicion remains. As with every test on this site, ranges vary by laboratory, and calcitonin assays vary more than most.

What the boxed warning says

Each label opens with the same warning. In rodents, the drug caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether the drug causes C-cell tumors, including MTC, in humans, because human relevance of the rodent finding has not been determined. The drug is contraindicated in patients with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients on the potential risk and the symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, shortness of breath, persistent hoarseness.

What the same section says about testing

Section 5.1 of each label continues: routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with the drug. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin may indicate MTC, and patients with MTC usually have calcitonin values greater than 50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.

Four things follow from that paragraph.

1. No routine test. Not calcitonin, not ultrasound.
2. The reason is stated. Calcitonin has low specificity: many things raise it mildly (kidney disease, some medicines, smoking, other thyroid conditions), and thyroid nodules are common in the general population. A screening programme would find a lot of both and lead to biopsies and operations that would not have been needed.
3. A number is given for context. Greater than 50 ng/L (the same as pg/mL) is where the label puts "usually" for MTC. That is not a cut-off for a test nobody is asking you to take; it is guidance for a clinician holding a result that was obtained for some other reason.
4. Nodules are different. A lump found on examination or on imaging done for another reason is evaluated, on GLP-1 therapy or off it.

The contraindication that does the work

The part of the thyroid warning that changes prescribing is not a lab test. It is a question: do you, or does anyone in your family, have a history of medullary thyroid carcinoma or MEN 2? MEN 2 is an inherited syndrome that causes MTC in nearly everyone who carries it. If the answer is yes, the drug is contraindicated and the question of monitoring does not arise. If you are not sure about your family history, ask relatives before the first visit; "thyroid cancer" in a relative is usually papillary or follicular cancer, which is not MTC and is not the contraindication, but the prescriber needs the detail.

When calcitonin is drawn

• You have a thyroid nodule and an endocrinologist is working it up. Calcitonin is part of some nodule evaluations independently of GLP-1 therapy.
• A raised calcitonin already exists from testing done for another reason, and it is being followed.
• Your prescriber chooses to order one despite the label's position. That is their discretion. The label's instruction on a raised result then applies: evaluate further, which means an endocrinology referral, not a repeat and a shrug.

What to report, at any point during therapy

A lump or swelling in the neck, difficulty swallowing, shortness of breath not explained by anything else, hoarseness that lasts. These are the label's symptom list. Report them to your prescriber; do not wait for a scheduled visit.

What to discuss with your prescriber

• Your personal and family history of MTC and MEN 2, with as much detail as you can gather.
• Any known thyroid nodule, and whether it has been evaluated.
• If a calcitonin was drawn and is above the lab's range: who will evaluate it and how.

The TSH page explains why a normal thyroid function test says nothing about C cells. The boxed warning is on the brand labels; compounded semaglutide and tirzepatide, including products from FormBlends, are not FDA approved and carry no FDA-reviewed warning, which is a reason to treat the brand warning as applying in full.